The AI in pharmaceutical market is anticipated to garner notable gains, registering a CAGR of 29.4% every year, according to a 2022 study by Precedence Research, the Canada-based market Insight Company.
The AI in pharmaceutical market is surging, with an overall revenue growth expectation of hundreds of billions of dollars within the next ten years. The market is expected to grow to US$ 9,241.34 million by 2030 from US$ 905.91 million in 2021. The report contains 150+ pages with detailed analysis.
The rapid adoption of the AI technologies in the pharmaceutical industry across the globe is the primary driver of the AI in the pharmaceutical market. The rising investments in the biopharmaceutical industry to cater the burgeoning demand for the innovative drugs that cures various chronic diseases such as cancer, diabetes, and CVDs is exponentially driving the adoption of AI in the pharmaceutical market.
The use of AI technologies can enhance the research & development, clinical trials, and the drug manufacturing processes allowing the pharmaceutical companies to significantly reduce cost and time. Majority of the global pharmaceutical players are increasing investments in the adoption of the AI technologies. For instance, in April 2021, Abbott introduced its new coronary imaging platform, powered by artificial intelligence, in Europe. It has also received CE mark by the concerned authorities in Europe. Therefore, the demand for AI technologies in the pharmaceutical industry is expected to grow at a significant rate.
Our Free Sample Reports Includes:
- In-depth Industry Analysis, Introduction, Overview, and COVID-19 Pandemic Outbreak.
- Impact Analysis 180+ Pages Research Report (Including latest research).
- Provide chapter-wise guidance on request 2021 Updated Regional Analysis with Graphical Representation of Trends, Size, & Share, Includes Updated List of figures and tables.
Updated Report Includes Major Market Players with their Sales Volume, Business Strategy and Revenue Analysis by using Precedence Research methodology.
Download a FREE Sample Copy (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1485
AI in Pharmaceutical Market Scope
|Market Size in 2020||USD 701.6 Million|
|Growth Rate from 2021 to 2030||29.4%|
|Revenue Projection by 2030||USD 9,241.34 Million|
|Largest Market||North America|
|Fastest Growing Market||Asia Pacific|
|Forecast Period||2021 to 2030|
AI in Pharmaceutical Market Report Highlights
- Based on the technology, deep learning dominated the market with more than 33% of the market share in 2020. This is attributable to the increased adoption of the deep learning technology in the diagnosis and monitoring of the health conditions. It is extensively used in the monitoring of the health conditions and predicting the subsequent conditions in the near future. The rising adoption of this technology for monitoring the conditions related to various diseases such as sepsis and cardiovascular diseases is further fueling the growth of this segment.
- Based on the drug type, the large molecule is estimated to be the most opportunistic segment. The growing demand for the biologics for the treatment of various chronic diseases coupled with the rising prevalence of diseases, rising healthcare expenditure, and growing awareness regarding the biologic drugs is expected to foster the market growth.
- Based on the application, the drug discovery segment accounted for around 80% of the market share in 2020. The AI technologies facilitate cost reduction, savings of time, and increased operational efficiency in the drug discovery process, which has augmented the growth of this segment.
AI in Pharmaceutical Market Regional Snapshot
North America garnered a market share of around 43% in 2020. North America is characterized by the higher demand for the biopharmaceutical and biologics medications owing to the increased prevalence of various chronic diseases and increased healthcare expenditure. This creates a huge pressure on the biopharma companies to manufacture innovative drugs and at a rapid pace. The AI technologies can significantly boost the research, drug discovery, and drug manufacturing process by reducing the time consumption and costs involved in the drug development.
Moreover, the regulatory framework in the US is encouraging the healthcare and the pharmaceutical industries to increasingly adopt the AI powered technologies to increase operational efficiency and reduce costs. These factors had resulted in the dominance of the region in AI in the pharmaceutical market.
On the other hand, Asia Pacific is estimated to be the most opportunistic segment during the forecast period. This is attributed to the increasing presence of the CROs and the CMOs in countries like China, India, South Korea, and Singapore. The government policies to attract FDIs is fueling the adoption of the AI technologies in the research and manufacturing of the pharmaceutical drugs. The presence of the several top pharmaceutical manufacturing facilities in the Asia Pacific region is expected to boost the demand for the AI technologies in the forthcoming years.
Read Also: In-Vitro Fertilization Market Size May Hit US$ 33 billion by 2030
AI in Pharmaceutical Market Dynamics
Increasing usage of AI in drug discovery
The adoption of the AI and the machine learning technologies is growing rapidly in the drug discovery. The drug discovery has become extremely expensive and highly competitive in the past few years. Therefore, the rising demand for controlling cost and reducing time along with increasing the efficiency in the process related to the drug discovery is expected to drive the growth of the AI in the pharmaceutical market during the forecast period. Moreover, the AI and ML technologies assists in the research and developmental activities by reducing the errors and inefficiencies.
High capital investments in AI technologies
A huge capital investment is involved in the implementation of the AI and ML technologies in the pharmaceutical sector. The financial restrictions of the small and medium size pharmaceutical companies and drug manufacturers may restrict the adoption of AI and can hinder the market growth during the forecast period.
Rising investments in the drug discovery for chronic diseases
It is estimated that by 2025, around 50% of global pharmaceutical companies will deploy AI technologies. This will result in the increased investments in the development of the drugs for curing various oncology and chronic diseases. Therefore, the increased demand for the innovative drugs across the globe owing to the rising prevalence of various chronic diseases is expected to offer lucrative growth opportunities to the market players in the upcoming future.
Challenges of maintaining data security and data privacy
The data privacy and security are the most important factor for any big pharmaceutical organization. With the growing adoption of the digital technologies, the threat of cyberattacks is growing rapidly. The cyberattacks can adversely impact the organizations and can result in financial losses. Therefore, the maintenance of data security and privacy are the major challenges.
Some of the prominent players in the global AI in pharmaceutical market include:
- IBM Corporation
- Deep Genomics
- Cloud Pharmaceuticals, Inc.
- Microsoft Corporation
- NVIDIA Corporation
- Insilico Medicine
- Alphabet Inc.
- Atomwise, Inc.
Segments Covered in the Report
- Natural Language Processing
- Context-Aware Processing
- Deep Learning
- Querying Method
By Drug Type
- Large Molecules
- Small Molecules
- Drug Discovery
- Clinical Trial
- Research & Development
- North America
- Asia Pacific
- South Korea
- Rest of the World
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1485
You can place an order or ask any questions, please feel free to contact at firstname.lastname@example.org | +1 9197 992 333